{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:53:46Z","timestamp":1787496826654,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T00:00:00Z","timestamp":1563408000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pediatr"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12887-019-1602-8","type":"journal-article","created":{"date-parts":[[2019,7,18]],"date-time":"2019-07-18T08:02:42Z","timestamp":1563436962000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Describing vancomycin serum levels in pediatric intensive care unit (ICU) patients: are expected goals being met"],"prefix":"10.1186","volume":"19","author":[{"given":"Talita Muniz","family":"Maloni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9435-6267","authenticated-orcid":false,"given":"Talita Rantin","family":"Belucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra Regina","family":"Malagutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme Henrique Campos","family":"Furtado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,7,18]]},"reference":[{"issue":"7","key":"1602_CR1","first-page":"509","volume":"76","author":"N Petrosillo","year":"2010","unstructured":"Petrosillo N, Drapeau CM, Agrafiotis M, Falagas ME. Some current issues in the pharmacokinetics\/pharmacodynamics of antimicrobials in intensive care. Minerva Anestesiol. 2010;76(7):509\u201324 Available from: \n                    https:\/\/www.minervamedica.it\/en\/getfreepdf\/OhIWzyR%252F3FEesM8%252FWLkt%252BH%252F4wNzF2DYgLyF3ePPMjsH2QXc3OPJ1HW6wdFZrs5NfA3SjzWbFfULepL7QrsLOcg%253D%253D\/R02Y2010N07A0509.pdf\n                    \n                  .","journal-title":"Minerva Anestesiol"},{"issue":"9","key":"1602_CR2","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1093\/cid\/cir547","volume":"53","author":"AM Milstone","year":"2011","unstructured":"Milstone AM, Goldner BW, Ross T, Shepard JW, Carroll KC, Perl TM. Methicillin-resistant Staphylococcus aureus colonization and risk of subsequent infection in critically ill children: importance of preventing nosocomial methicillin-resistant Staphylococcus aureus transmission. Clin Infect Dis. 2011 Nov;53(9):853\u20139. \n                    https:\/\/doi.org\/10.1093\/cid\/cir547\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"4","key":"1602_CR3","doi-asserted-by":"publisher","first-page":"e1015","DOI":"10.1542\/peds.2013-3413","volume":"133","author":"FN Zervou","year":"2014","unstructured":"Zervou FN, Zacharioudakis IM, Ziakas PD, Mylonakis E. MRSA colonization and risk of infection in the neonatal and pediatric ICU: a meta-analysis. Pediatrics. 2014 Apr;133(4):e1015\u201323. \n                    https:\/\/doi.org\/10.1542\/peds.2013-3413\n                    \n                  .","journal-title":"Pediatrics."},{"key":"1602_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1186\/2047-783X-15-12-533","volume":"15","author":"KS Estes","year":"2010","unstructured":"Estes KS, Derendorf H. Comparison of the pharmacokinetic properties of vancomycin, linezolid, tigecyclin, and daptomycin. Eur J Med Res. 2010;15:533\u201343.","journal-title":"Eur J Med Res"},{"issue":"1","key":"1602_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/11596390-000000000-00000","volume":"51","author":"A Marsot","year":"2012","unstructured":"Marsot A, Boulamery A, Bruguerolle B, Simon N. Vancomycin: a review of population pharmacokinetic analyses. ClinPharmacokinet. 2012;51(1):1\u201313.","journal-title":"ClinPharmacokinet"},{"issue":"3","key":"1602_CR6","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1086\/600877","volume":"49","author":"MJ Rybak","year":"2009","unstructured":"Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, Dalovisio JR, Levine DP. Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2009;49(3):325\u20137. \n                    https:\/\/doi.org\/10.1086\/600877\n                    \n                  .","journal-title":"Clin Infect Dis"},{"issue":"13","key":"1602_CR7","doi-asserted-by":"publisher","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","volume":"43","author":"PA Moise-Broder","year":"2004","unstructured":"Moise-Broder PA, Forrest A, Birmingham MC, Schentag JJ. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925\u201342. \n                    https:\/\/doi.org\/10.2165\/00003088-200443130-00005\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"1602_CR8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1097\/INF.0b013e3181906e40","volume":"28","author":"A Frymoyer","year":"2009","unstructured":"Frymoyer A, Hersh AL, Benet LZ, Guglielmo BJ. Current recommended dosing of vancomycin for children with invasive methicillin-resistant Staphylococcus aureus infections is inadequate. Pediatr Infect Dis J. 2009;28(5):398\u2013402. \n                    https:\/\/doi.org\/10.1097\/INF.0b013e3181906e40\n                    \n                  .","journal-title":"Pediatr Infect Dis J"},{"issue":"5","key":"1602_CR9","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1345\/aph.1P588","volume":"45","author":"Lea S Eiland","year":"2011","unstructured":"Eiland LS, English TM, Eiland EH 3rd. Assessment of vancomycin dosing and subsequent serum concentrations in pediatric patients. Ann Pharmacother 2011;45(5):582\u2013589. doi: \n                    https:\/\/doi.org\/10.1345\/aph.1P588\n                    \n                  .","journal-title":"Annals of Pharmacotherapy"},{"issue":"10","key":"1602_CR10","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1097\/INF.0b013e318299f75c","volume":"32","author":"A Frymoyer","year":"2013","unstructured":"Frymoyer A, Guglielmo BJ, Hersh AL. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant staphylococcal infections. Pediatr Infect Dis J. 2013;32(10):1077\u20139. \n                    https:\/\/doi.org\/10.1097\/INF.0b013e318299f75c\n                    \n                  .","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"1602_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.5863\/1551-6776-22.1.41","volume":"22","author":"OA Kishk","year":"2017","unstructured":"Kishk OA, Lardieri AB, Heil EL, Morgan JA. Vancomycin AUC\/MIC and Corresponding troughs in a pediatric population. J Pediatr Pharmacol Ther. 2017;22(1):41\u20137. \n                    https:\/\/doi.org\/10.5863\/1551-6776-22.1.41\n                    \n                  .","journal-title":"J Pediatr Pharmacol Ther"},{"issue":"11","key":"1602_CR12","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.2165\/00003088-200645110-00003","volume":"45","author":"IH Bartelink","year":"2006","unstructured":"Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet. 2006;45(11):1077\u201397. \n                    https:\/\/doi.org\/10.2165\/00003088-200645110-00003\n                    \n                  .","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"1602_CR13","doi-asserted-by":"publisher","first-page":"e250","DOI":"10.1097\/PCC.0b013e3181fe4047","volume":"12","author":"GA Giachetto","year":"2011","unstructured":"Giachetto GA, Telechea HM, Speranza N, Oyarzun M, Nanni L, Menchaca A. Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children. Pediatr Crit Care Med. 2011;12(6):e250\u20134. \n                    https:\/\/doi.org\/10.1097\/PCC.0b013e3181fe4047\n                    \n                  .","journal-title":"Pediatr Crit Care Med"},{"issue":"4","key":"1602_CR14","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1097\/INF.0b013e318286378e","volume":"32","author":"J Le","year":"2013","unstructured":"Le J, Bradley JS, Murray W, Romanowski GL, Tran TT, Nguyen N, Cho S, Natale S, Bui I, Tran TM, Capparelli EV. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013;32(4):e155\u201363. \n                    https:\/\/doi.org\/10.1097\/INF.0b013e318286378e\n                    \n                  .","journal-title":"Pediatr Infect Dis J"},{"key":"1602_CR15","volume-title":"Generalized, linear, and mixed models","author":"CE McCulloch","year":"2005","unstructured":"McCulloch CE, Searle SR. Generalized, linear, and mixed models. New York: John Wiley and Sons Ltd.; 2005."},{"key":"1602_CR16","volume-title":"SPSS statistics for windows [computer program]. Version 17.0","author":"SPSS Inc","year":"2008","unstructured":"SPSS Inc. SPSS statistics for windows [computer program]. Version 17.0. Chicago: SPSS Inc.; 2008."},{"key":"1602_CR17","volume-title":"R: a language and environment for statistical computing [internet]","author":"R Core Team","year":"2014","unstructured":"R Core Team. R: a language and environment for statistical computing [internet]. Vienna (AT): R Foundation for Statistical Computing; 2014. Available from: \n                    http:\/\/www.R-project.org\/"},{"key":"1602_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s40272-018-0282-4","volume":"20","author":"S Tkachuk","year":"2018","unstructured":"Tkachuk S, Collins K, Ensom MHH. The relationship between vancomycin trough concentrations and AUC\/MIC ratios in pediatric patients: a qualitative systematic review. Pediatr Drugs. 2018;20:153 \n                    https:\/\/doi.org\/10.1007\/s40272-018-0282-4\n                    \n                  .","journal-title":"Pediatr Drugs"},{"issue":"1","key":"1602_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.2146\/ajhp080434","volume":"66","author":"M Rybak","year":"2009","unstructured":"Rybak M, Lomaestro B, Rotschafer JC, Moellering R Jr, Craig W, Billeter M, Dalovisio JR, Levine DP. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009;66(1):82\u201398. \n                    https:\/\/doi.org\/10.2146\/ajhp080434\n                    \n                  .","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"1602_CR20","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1093\/cid\/cir034","volume":"52","author":"Catherine Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, Kaplan SL, Karchmer AW, Levine DP, Murray BE, J. Rybak M, Talan DA, Chambers HF. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. Clin Infect Dis 2011;52(3):285\u2013292. doi: \n                    https:\/\/doi.org\/10.1093\/cid\/cir034.","journal-title":"Clinical Infectious Diseases"},{"issue":"12","key":"1602_CR21","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1097\/INF.0b013e31826a3eaf","volume":"31","author":"CL Gordon","year":"2012","unstructured":"Gordon CL, Thompson C, Carapetis JR, Turnidge J, Kilburn C, Currie BJ. Trough concentrations of vancomycin: adult therapeutic targets are not appropriate for children. Pediatr Infect Dis J. 2012;31(12):1269\u201371. \n                    https:\/\/doi.org\/10.1097\/INF.0b013e31826a3eaf\n                    \n                  .","journal-title":"Pediatr Infect Dis J"},{"issue":"12","key":"1602_CR22","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1002\/phar.1331","volume":"33","author":"T Madigan","year":"2013","unstructured":"Madigan T, Sieve RM, Graner KK, Banerjee R. The effect of age and weight on vancomycin serum trough concentrations in pediatric patients. Pharmacotherapy. 2013;33(12):1264\u201372. \n                    https:\/\/doi.org\/10.1002\/phar.1331\n                    \n                  .","journal-title":"Pharmacotherapy."},{"issue":"6","key":"1602_CR23","first-page":"416","volume":"67","author":"J Hoang","year":"2014","unstructured":"Hoang J, Dersch-Mills D, Bresee L, Kraft T, Vanderkooi OG. Achieving therapeutic vancomycin levels in pediatric patients. Can J Hosp Pharm. 2014;67(6):416\u201322.","journal-title":"Can J Hosp Pharm"},{"issue":"3","key":"1602_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.5863\/1551-6776-14.3.154","volume":"14","author":"T McCabe","year":"2009","unstructured":"McCabe T, Davis G, Iocono J, Nelson C, Kuhn R. Evaluating the empiric dose of vancomycin in pediatric patients [abstract]. In: 18th annual meeting abstracts. J Pediatr Pharmacol Ther. 2009;14(3):167\u20138. \n                    https:\/\/doi.org\/10.5863\/1551-6776-14.3.154\n                    \n                  .","journal-title":"J Pediatr Pharmacol Ther"},{"key":"1602_CR25","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.addr.2014.07.006","volume":"77","author":"SI Blot","year":"2014","unstructured":"Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient--concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3\u201311. \n                    https:\/\/doi.org\/10.1016\/j.addr.2014.07.006\n                    \n                  .","journal-title":"Adv Drug Deliv Rev"},{"key":"1602_CR26","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/IDR.S121513","volume":"9","author":"W Katip","year":"2016","unstructured":"Katip W, Jaruratanasirikul S, Pattharachayakul S, Wongpoowarak W, Jitsurong A, Lucksiri A. The pharmacokinetics of vancomycin during the initial loading dose in patients with septic shock. Infect Drug Resist. 2016;9:253\u201360. \n                    https:\/\/doi.org\/10.2147\/IDR.S121513\n                    \n                  .","journal-title":"Infect Drug Resist"},{"issue":"3","key":"1602_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.5414\/CPP46140","volume":"46","author":"M Vazquez","year":"2008","unstructured":"Vazquez M, Fagiolino P, Boronat A, Buroni M, Maldonado C. Therapeutic drug monitoring of vancomycin in severe sepsis and septic shock. Int J Clin Pharmacol Ther. 2008;46(3):140\u20135.","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"5","key":"1602_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ijantimicag.2010.01.023","volume":"35","author":"A Barbour","year":"2010","unstructured":"Barbour A, Scaglione F, Derendorf H. Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic\/pharmacodynamic indices. Int J Antimicrob Agents. 2010;35(5):431\u20138. \n                    https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.01.023\n                    \n                  .","journal-title":"Int J Antimicrob Agents"},{"issue":"Suppl 2","key":"1602_CR29","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1016\/j.ijantimicag.2010.11.011","volume":"36","author":"F Scaglione","year":"2010","unstructured":"Scaglione F. Pharmacokinetic\/pharmacodynamic (PK\/PD) considerations in the management of gram-positive bacteraemia. Int J Antimicrob Agents. 2010;36(Suppl 2):S33\u20139. \n                    https:\/\/doi.org\/10.1016\/j.ijantimicag.2010.11.011\n                    \n                  .","journal-title":"Int J Antimicrob Agents"}],"container-title":["BMC Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-019-1602-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12887-019-1602-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12887-019-1602-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T19:06:33Z","timestamp":1594926393000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpediatr.biomedcentral.com\/articles\/10.1186\/s12887-019-1602-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,18]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1602"],"URL":"https:\/\/doi.org\/10.1186\/s12887-019-1602-8","relation":{},"ISSN":["1471-2431"],"issn-type":[{"value":"1471-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,18]]},"assertion":[{"value":"18 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Ethics Committee of the Instituto Israelita de Pesquisa Albert Einstein. The requirements for informed consent were waived by our IRB in accordance of the Code of Federal Regulation and of the Privacy Rule.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. This research received no specific grant from any funding agency in the public, commercial, or non-for-profit sectors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"240"}}